Mangalam Drugs And Organics Limited has informed the Exchange regarding Board meeting held on November 20, 2025. Outcome of Un-Audited Financials with Limited Review Report.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mangalam Drugs and Organics Limited held a board meeting on November 20, 2025, to approve its unaudited financial results accompanied by a limited review report from its statutory auditors. Limited review reports are the standard auditor attestation provided for quarterly/half-yearly results and are less detailed than a full annual audit. The specific financial figures, revenue, profit after tax, and segment details would be contained in the filed results document, which is not provided here. This is a routine regulatory compliance filing under SEBI's listing obligations, signaling timely disclosure of periodic financials. Shareholders should refer to the detailed results PDF for the actual numbers and any management commentary.
This is a procedural disclosure confirming that the company has met its quarterly/periodic financial reporting deadline. No immediate impact on shareholders or stock price is implied from the filing itself — actual impact would depend on the numbers in the detailed results.